Our Services
Clinical Trial Management Services
Central Laboratory Services
Clinical Pharmacology
Scintigraphy
Pharmacovigilance
Regulatory Affairs
Clinical & Medical Writing
Clinical Trial Management Services
Phase I
Phase II
Phase III
Site Management & Monitoring
IMP Management
Biometric Services
We worked with KalVista Pharmaceuticals to study Oral KVD900 in Patients with Hereditary Angioedema (HAE) in this phase II clinical trial. Results included the observation that attacks treated with KVD900 significantly reduced use of rescue with 15% of KVD900 treated attacks rescued compared to 30% on placebo at 12 hours.
